HCC (Hepatocellular Carcinoma) Market Size (2025 – 2030)

The Global HCC (Hepatocellular Carcinoma) Market was valued at USD 3.5 billion in 2024 and is projected to reach a market size of USD 9.85 billion by the end of 2030. Over the forecast period of 2025-2030, the market is projected to grow at a CAGR of 22.99%. 

Hepatocellular carcinoma, HCC is an oncological disease resulting from the multiplication of cancerous cells in the hepatocytes or liver cells. It is a rather dangerous illness that can destroy hepatic cells and interfere with their functions to put dangerous complications in the way of life. Depending on the HCC stage and size, the symptoms might change, and a lot of patients may have no signs. Some of the non-specific symptoms include abdominal pain, nausea, vomiting, tiredness, etc. Patients with hepatocellular carcinoma may also present with yellow skin, loss of appetite, abdominal swelling, unintentional weight loss, easy bruising, etc. The diagnosis of this disease is usually based on the patient's symptoms, blood testing, and imaging evaluation. The healthcare provider may also perform numerous diagnostic procedures, such as multi-phase computerized tomography scans and contrast-enhanced magnetic resonance imaging, to detect disease staging among patients. Additionally, a biopsy or ultrasound of the tumor is required to confirm the diagnosis of hepatocellular carcinoma. The latest research from IMARC Group offers a thorough examination of the hepatocellular carcinoma markets in the US, UK, Japan, and EU4 (Germany, Spain, Italy, and France). Treatment methods, in-market, and pipeline medications, the market share of specific therapies, the performance of the seven main markets, the performance of important firms and their medications, etc. are all included in this. The patient pool for the seven main markets, both present and future, is also included in the report. The survey claims that both the patient pool and the market for hepatocellular carcinoma treatment are the largest in the United States. The study has also included information on the existing treatment practice/algorithm, market drivers, opportunities, challenges, reimbursement scenarios, unmet medical needs, etc.

Key Market Insights:

• Positive results from Geneos Therapeutics' Phase I/II GT-30 clinical study of GNOS-PV02, a customized neoantigen vaccine, in conjunction with pembrolizumab for advanced hepatocellular cancer, were reported in April 2024. Nearly one-third of patients treated with this combination therapy showed tumor shrinking, according to the findings, and three of those patients achieved a complete response, meaning that after a median follow-up of 21.5 months, no visible tumor indications remained.

• At the 2023 AASLD Liver Meeting in Boston, Massachusetts, in November 2023, SCG Cell Therapy Pte Ltd (SCG) unveiled late-breaking clinical results from its first-in-class autologous hepatitis B virus (HBV)-specific T-cell receptor-engineered T Cell (TCR-T) treatment, SCG101. SCG101 showed possible antiviral and anticancer effects in individuals with advanced HBV-related hepatocellular carcinoma in a first-in-human clinical trial.

• Tvardi Therapeutics, Inc. announced in June 2023 that the first subjects in each arm of its ongoing REVERT LIVER CANCER research had received their doses. In patients with locally advanced or metastatic and incurable hepatocellular carcinoma, the trial assesses the safety and therapeutic efficacy of TTI-101 both as a monotherapy and in combination with standard-of-care treatment.

• Genoscience Pharma said in February 2023 that the US FDA has granted their top candidate, ezurpimtrostat, a PPT-1 (Palmitoyl Protein Thioesterase-1) inhibitor, Orphan Drug Designation (ODD) for the treatment of hepatocellular cancer

HCC (Hepatocellular Carcinoma) Market Drivers:

The growing prevalence of lifestyle diseases is one of the major drivers of the hepatocellular carcinoma treatment market growth.

The liver is greatly impacted by lifestyle disorders like diabetes, obesity, and high blood pressure, which are also some of the main causes of hepatocellular carcinoma. The need for hepatocellular carcinoma treatment will increase due to the growing prevalence of lifestyle illnesses. One of the main forms of liver disease is non-alcoholic fatty liver disease (NAFLD). In Western nations, NAFLD affects 20% to 30% of the general population, according to the NIH. Additionally, those who have type 2 diabetes (70%) and obesity (90%) have higher prevalence rates of NAFLD. Since the prevalence of NAFLD has a significant impact on hepatocellular carcinoma, if treatment is not received, the market for hepatocellular carcinoma treatments will eventually benefit from the high prevalence of lifestyle illnesses.

The high availability of therapies and chemotherapy drugs is giving rise to market growth.

The industry is changing as a result of new technology being included in non-melanoma skin cancer treatment devices. Cutting-edge technologies like photodynamic therapy (PDT), laser therapy, and cryotherapy offer non-invasive treatment options that precisely target cancerous cells with the least amount of tissue damage possible. Robotic surgery enhances surgical precision in challenging situations, and artificial intelligence (AI) increases diagnostic accuracy by enabling early detection. Additionally, follow-up therapy and remote patient monitoring are made possible via wearable technology and telemedicine systems. The market for non-melanoma skin cancer is expanding as a result of these technological advancements, which are also boosting treatment results, reducing recovery times, and enhancing patient comfort.

HCC (Hepatocellular Carcinoma) Market Restraints and Challenges:

Aversion to Side Effects, as well as the high cost involved, will Limit Market Growth.

One of the main obstacles to the expansion of the hepatocellular carcinoma treatment market is the high side effects of the existing medicines, particularly chemotherapy medications. In addition to decreasing patient compliance, severe adverse effects of liver disease treatment medications may also lead to patient dropouts, which lowers demand for the medications and, ultimately, their sales. These medications come in a variety of combinations and dose formats. Common adverse effects include sleepiness, alopecia, urine retention, dry eyes, dry mouth, diarrhea, and visual impairment. When giving these medications to older people who have dementia or cognitive impairment, care must be exercised because the medications may exacerbate their symptoms. Even though these medications are prescribed to children, taking more of them than is allowed can have major negative effects. Urinary tract infections and headaches are the most often reported adverse effects. Constipation, diarrhea, rash, abdominal pain, and heart palpitations are a few uncommon adverse effects. Consequently, the possible adverse effects of hepatocellular carcinoma medications hinder the justification for their usage in treating the disease, which has a detrimental effect on the market's expansion.

HCC (Hepatocellular Carcinoma) Market Opportunities:

The market for hepatocellular carcinoma (HCC) offers a number of encouraging prospects for expansion and advancement. The need for HCC treatments is growing as chronic liver illnesses including hepatitis B and C and non-alcoholic fatty liver disease (NAFLD) become more common. Patient outcomes are being improved by new treatment choices like as immunotherapy, targeted treatments, and minimally invasive procedures. Advances in AI and machine learning in particular are improving diagnostic precision and making it possible to identify HCC early. Growing awareness and advancements in healthcare infrastructure indicate substantial development potential in emerging economies in Latin America and Asia-Pacific. Patients with HCC now have new hope thanks to research and development initiatives that are producing innovative medications and therapies. Patient satisfaction and treatment effectiveness are increasing as a result of customized treatment programs made to fit each patient's unique profile. New medicines are being developed more quickly thanks to strategic alliances and collaborations between pharmaceutical corporations, academic institutions, and healthcare providers. In the upcoming years, it is anticipated that these changes will propel the expansion of the HCC market and enhance patient outcomes.

HCC MARKET REPORT COVERAGE:

HCC (Hepatocellular Carcinoma) Market Segmentation: Treatment Type

• Interventional Radiology

• Chemotherapy

• Radiation Therapy

• Surgery

• Targeted Therapy

• Immunotherapy

The market for hepatocellular carcinoma (HCC) is divided into therapeutic categories, each of which offers a unique strategy for treating the condition. Interventional radiology encompasses minimally invasive techniques that directly target cancer cells, such as radiofrequency ablation, chemoembolization, and intra-arterial chemotherapy. Interventional radiology is becoming more and more in demand because of its accuracy and effectiveness in treating localized malignancies. Chemotherapy is still an essential aspect of treating HCC, especially when the disease is advanced and surgery is not an option. It is frequently used either alone or in conjunction with other medications, despite its negative consequences. The precision and efficacy of radiation therapy, which utilizes high-energy radiation to kill cancer cells, have increased, making it a good choice for patients who are unable to have surgery. For localized HCC, surgical excision is another popular therapeutic option. Liver transplantation may also be explored in certain circumstances. Success rates have increased dramatically as a result of improvements in surgical methods and post-operative care. A significant advancement in the treatment of HCC targeted therapies targets certain chemicals implicated in the formation of cancer and offers safer and more effective alternatives to conventional chemotherapy. Immunocheckpoint inhibitors are increasingly being used in immunotherapy, which boosts the body's immune system to combat cancer cells. Immunotherapy has had encouraging outcomes, especially in advanced stages. All of these therapy options are essential to the overall management of HCC because they enable individualized strategies based on the needs of the patient and the course of the disease.

HCC (Hepatocellular Carcinoma) Market Segmentation: By End User

• Hospitals

• Clinics

• Cancer Rehabilitation Centers

• Ambulatory Surgery Centers

End users, who are essential to patient care and treatment delivery, make up the market for hepatocellular carcinoma (HCC). Because they provide access to trained oncologists, multimodal treatment techniques, and sophisticated diagnostic technologies, hospitals serve as the main treatment facilities for HCC. They deal with a lot of situations, especially those involving radiation therapy, chemotherapy, and surgery. Clinics act as secondary care providers, emphasizing follow-up care for patients receiving long-term management, early diagnosis, and outpatient therapies. Cancer rehabilitation facilities focus on post-treatment care, enhancing patients' quality of life by providing physical therapy, dietary guidance, and psychological support.
 

HCC (Hepatocellular Carcinoma) Market Segmentation: Regional Analysis

• North America

• Europe

• Asia-Pacific

• Latin America

• Middle East and Africa

Due to the rising incidence of chronic liver diseases and the growing number of clinical trials for cancer treatment conducted by manufacturers to meet patients' unmet medical needs, North America is anticipated to maintain a leading position in the global market for hepatocellular carcinoma treatment during the forecast period. According to a 2017 survey by the University of California, Los Angeles' (UCLA) Health Science Department, hepatocellular carcinoma (HCC) accounts for over 70.0% of all liver cancer diagnoses in the United States. An estimated 40,000 people received a liver cancer diagnosis in 2017, and more than 28,000 deaths were attributed to HCC. Because more manufacturers in the area are conducting research and development to create efficient medicines and treatment methods for hepatocellular carcinoma, Europe and Asia Pacific are anticipated to see a notable compound annual growth rate (CAGR) over the projected period. The World Health Organization estimates that 36,000 persons in Japan and 63,000 in Europe received a liver cancer diagnosis in 2017.

COVID-19 Impact Analysis on the Global HCC (Hepatocellular Carcinoma) Market:

The global market for hepatocellular carcinoma (HCC) has been significantly impacted by the COVID-19 pandemic. At first, the pandemic caused fewer HCC cases to be diagnosed and treated because medical resources were diverted to treating COVID-19 cases. The detection and treatment of HCC were delayed as a result of the cancellation or postponement of numerous elective procedures and routine examinations. However, the need for HCC therapies increased again as healthcare systems adjusted to the new normal. The quicker uptake of telemedicine and remote monitoring, which enabled patients to continue their therapy without frequent hospital stays, has been one benefit. The epidemic also brought attention to the significance of a strong healthcare system and the demand for cutting-edge therapeutic approaches. New medications and treatments for HCC were approved as a result of pharmaceutical companies' greater emphasis on research and development. All things considered, even while the pandemic originally caused problems with HCC therapy, it also spurred improvements in healthcare delivery and available treatments, which eventually helped HCC patients.
Latest Trends/ Developments:

The market for non-melanoma skin cancer is expanding significantly in 2024 as a result of a number of developments and trends. New therapies like checkpoint inhibitors and bispecific antibodies are demonstrating encouraging outcomes for advanced cases as immunotherapy continues to advance. With up to 95% accuracy rates, AI-driven diagnostics are improving the identification of skin cancer. Because they provide accurate targeting and treatment, minimally invasive surgical procedures like image-guided superficial radiation therapy are growing in popularity. Programs for screening and greater awareness are essential for early detection, which improves patient outcomes. Because of greater knowledge and advancements in healthcare infrastructure, emerging regions in Asia-Pacific and Latin America exhibit substantial development potential. Additionally, patients who might not be good candidates for surgery now have additional therapeutic alternatives thanks to the development of innovative topical medicines and photodynamic therapies. New medicines are being developed more quickly thanks to strategic alliances and collaborations between pharmaceutical corporations, academic institutions, and healthcare providers. Personalized treatment regimens that cater to each patient's specific needs are becoming increasingly prevalent as patient-centric care gains more attention. Additionally, the market is witnessing a surge in financing and expenditure for research and development, which is anticipated to propel additional improvements in the years to come.

Key Players:

1. Novartis AG

2. Bayer AG

3. Merck & Co

4. Celgene Corporation

5. Bristol- Myers Squibb

6. Amgen Inc.

7. Teva Pharmaceuticals Industries

8. AbbVie Inc.

9. Johnson & Johnson Services